John Strickler, MD, discusses targeting c-Met as a biomarker in gastric and gastroesophageal junction cancers.
John Strickler, MD
Advertisement
John Strickler, MD, is a medical oncologist with a focus on gastrointestinal cancers at Duke Cancer Center in Durham, NC.
Articles by John Strickler, MD
Advertisement
Latest Updated Articles
c-Met as a Biomarker in Gastric/GEJ CancersPublished: October 12th 2024 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
